Date/Time

Lecturer

Affiliation

Topic

9/11/07 

Stephen Howell, MD
Professor

UCSD

Introduction to Oncology Drug Development

9/18/07 

Web Cavenee, PhD
Professor

UCSD

Targeting Signaling Receptors in Cancer

9/20/07

Thursday

C. Frank Bennett, PhD
Senior Vice President, Research

ISIS Pharmaceuticals, Inc.

Oligonucleotides as Therapeutic Agents

9/25/2007

Roger Tsien, PhD
Professor

UCSD

Activatable Cell-Penetrating Peptides for Tumor Imaging and Therapy

10/2/07 

Xiang-Dong Fu, MD
Professor

UCSD

Genomic Approaches to Drug Development

10/9/07

Dennis Carson, MD
Director
Moores UCSD Cancer Center

UCSD

The Development and Mechanism of Action of Cladribine

10/11/07
Thursday

Ben Tseng, PhD
Chief Scientific Officer

EpiCept Corporation

Discovery to Phase I of EPC2407: A Small Molecule Anticancer Agent

10/16/07

Gordon Gill, MD
Professor of Medicine

UCSD

Tyrosine Kinase Inhibitors:  Profiling Tumors for Their Use

10/23/07

Grace Furman, PhD
President

Paracelsus, Inc.

Toxicology in Oncology Drug Development

10/30/07

Marc Nasoff, MD
Director, Biotherapeutics

UCSD

Functional Antibodies - Potent and Specific Signal Transduction Modulators 

11/2/07

Friday

Sinil Kim, MD
Director, Clinical Development

Pfizer
Pharmaceuticals

Axitinib

11/6/07

Karen Messer, MD
Associate Professor

UCSD
Family & Preventive Medicine

Designs for Early Stage Cancer Clinical Trials

11/13/07

William Gerwick, PhD
Professor 

UCSD
SIO

Anticancer Drug Discovery from the Marine Realm - Novel Molecules Working by Novel Mechanisms

11/20/07

Sanford Shattil, MD
Professor and Chief  

UCSD

Integrin Signaling and Drug Discovery

12/12/07
Wednesday

Laurie Strawn, PhD
Director, Regulatory Strategy 

Pfizer Pharmaceuticals

Regulatory Considerations in Oncology Drug Development: SUTENT as an example

1/8/08

Geoff Wahl, PhD
Professor

Salk Institute

Understanding the p53 Stress Response Pathway to Enable Development of Personalized Therapeutics